Category

Archives

CDK

Synthesis and evaluation of FAK inhibitors with a 5-fluoro-7H-pyrrolo[2,3-d]pyrimidine scaffold as anti-hepatocellular carcinoma agents

46 views | Oct 12 2021

Hanyi Tan et al. suggested that 16c inhibited the malignant proliferation of hepatocellular carcinoma (HCC) cells through decreasing the phosphorylation in the FAK cascade. [Read the Full Post]

Neoadjuvant Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors Combined with Endocrine Therapy in HR+/HER2- Breast Cancer: A Systematic Review and Meta-Analysis

24 views | Sep 29 2021

Kai Hong et al. suggested that combination therapy had increased efficacy and toxicity compared to endocrine monotherapy and showed similar efficacy to and better safety than neoadjuvant chemotherapy. [Read the Full Post]

Sarcomatoid hepatocellular carcinoma: From clinical features to cancer genome

57 views | Aug 04 2021

Cheng Zhang et al. thought that CDK4/6 inhibitors including abemaciclib, ribociclib and palbociclib as potential therapeutic targets and might help for therapeutic decision making. [Read the Full Post]

Targeting Pyruvate Kinase M2 phosphorylation reverses aggressive cancer phenotypes

121 views | Jul 19 2021

Maria Apostolidi et al. found that combinations of Dinaciclib with TEPP-46 reduced cell invasion, impaired redox balance, and triggered cancer cell death. [Read the Full Post]

The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time

115 views | Jul 19 2021

Mayu Ono et al. found that ER-positive breast cancer cells used multiple molecular mechanisms to survive in the presence of palbociclib. [Read the Full Post]

Patient-derived scaffolds as a drug-testing platform for endocrine therapies in breast cancer

55 views | Jun 28 2021

Anna Gustafsson et al. thought that the PDS technique was an up-scalable patient-derived drug-testing platform available for gene expression profiling and downstream functional assays. [Read the Full Post]

Non-hotspot PIK3CA mutations are more frequent in CLOVES than in common or combined lymphatic malformations

61 views | Jun 17 2021

Pascal Brouillard et al. demonstrated efficacy of Sirolimus and Alpelisib in treating patients with an LM or PROS. [Read the Full Post]

Treatment of liver cancer cells with ethyl acetate extract of Crithmum maritimum permits reducing sorafenib dose and toxicity maintaining its efficacy

63 views | May 21 2021

Davide Gnocchi et al. found that combined treatment with C. maritimum ethyl acetate extract and half IC50 sorafenib dose decreased cell proliferation comparably to full-dose sorafenib without increasing cell toxicity as confirmed by the effect on cell cycle regulation and apoptosis. [Read the Full Post]

KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from the in vitro experiments

59 views | May 16 2021

Takamasa Koga et al. thought that switching to BI-3406 plus trametinib might be a useful strategy to overcome acquired resistance due to the secondary Y96D/S mutation. [Read the Full Post]

Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor

65 views | May 07 2021

Su-Lin Lim et al. found that the combination of a BET PROTAC (ARV 825) plus AZD 4573 (CDK9 inhibitor) was effective against MM cells. [Read the Full Post]